IL-33R (ST2) Monoclonal Antibody (RMST2-2), APC, eBioscience™, Invitrogen™

Description

• Description: The RMST2-2 monoclonal antibody reacts with ST2, also known as IL-33 receptor (IL-33R) or interleukin 1 receptor-like 1
• ST2 is a member of the IL-1 receptor family
• In the membrane-bound form, it consists of three extra-cellular immunoglobulin domains and an intracellular toll-interleukin-1 receptor domain
• ST2 forms a dimer with IL-1R accessory protein in a ligand-dependent manner
• The IL-33/ST2 interaction induces the production of TH2 cytokines
• ST2 also has a soluble isoform lacking transmembrane and intracellular toll-interleukin-1 receptor domains
• It is believed that the soluble form functions as a decoy receptor that can block membrane bound IL-33/ST2 interaction
• ST2 is expressed by TH2 lymphocytes, mast cells, eosinophils, basophils, innate lymphocytes, smooth muscle cells, and endothelial cells and is involved in host defense, allergy, and inflammation
• The IL-33/ST2 interaction has also been shown to be atheroprotective
• Applications Reported: This RMST2-2 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This RMST2-2 antibody has been tested by flow cytometric analysis of mouse bone marrow-derived mast cells
• This can be used at less than or equal to 0.25 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• IL-33R, also known as ST2, is a receptor for IL-33
• It is a member of the IL-1 receptor family of innate receptors
• Its extracellular domain consists of 3 Ig-like domains that directly interact with its co-receptor IL-1RAcP, and the ligand alarmin, IL-33
• IL-33 ligation results in the association of IL-33R complex with its adaptor proteins MyD88, IRAK1, IRAK4 and TRAF6, and activation of the NF-kB, and MAPK pathways
• This, in turn, instigates the release of chemokines and cytokines such as IL-5, IL-6, IL-8, and IL-13
• Two most common isoforms of IL-33R that result from alternative splicing are ST2L – the membrane bound form, and ST2S – the soluble form
• The membrane bound form can be released from the cell surface by proteolytic cleavage
• The soluble forms have been suggested to act as decoys dampening the IL-33 signaling
• IL-33R is primarily expressed by mast cells, basophils, and eosinophils
• In mouse, IL-33R expression has been shown on ILC2 and Th2 cells
• IL-33R signaling has been implicated in the number of immune conditions, including allergies, arthritis, atherosclerosis and sepsis.